Susvimo Injection, Solution
Product Images NDC 50242-078

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Susvimo (NDC 50242-078). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Susvimo 01)

An instructional diagram showing the steps to attach a needle cap to a syringe, including aligning the needle, rotating the cap onto the syringe, and pulling to secure it. No text or product branding is visible.*

FDA Label Image

Susvimo 01a

An instructional illustration showing two hands holding a syringe with a needle pointing upward. The image appears to depict the preparation or handling of an injection, consistent with the intravitreal injection form of Susvimo (ranibizumab).*

FDA Label Image

Figure 2 (Susvimo 02)

Illustration showing the steps to attach and remove a blue needle cap from a syringe. The first step depicts removing the needle cap by pulling it straight down, the second shows twisting the cap, and the third demonstrates pulling the cap straight up off the syringe.*

FDA Label Image

Figure 3 (Susvimo 03)

An instructional diagram showing a hand holding a syringe with a close-up inset highlighting an air bubble inside the syringe. Another hand is shown tapping the syringe to move the air bubble. This image is related to preparation or administration of an injection, consistent with Susvimo, ranibizumab injection solution.*

FDA Label Image

Figure 4 (Susvimo 04)

An instructional line drawing showing two hands holding a syringe filled with medication. One hand steadies the syringe barrel while the other hand pulls back the plunger, illustrating a step in preparing an intravitreal injection.*

FDA Label Image

Figure 5 (Susvimo 05)

An instructional diagram showing a hand holding a syringe for intravitreal injection. The syringe chamber is highlighted with a close-up circle indicating ‘No air bubble’ at two points in the syringe barrel near the plunger and near the needle.*

FDA Label Image

Figure 6 (Susvimo 06)

Instructional illustration showing a hand holding a Susvimo injection device and another hand holding a syringe. An arrow indicates the syringe is to be inserted or connected to the injection device, demonstrating part of the preparation or administration process for the Susvimo ranibizumab intravitreal injection device.*

FDA Label Image

Figure 7 (Susvimo 07)

An instructional illustration showing a hand pulling a syringe filled with solution from a protective blue cover, indicated by a left-pointing gray arrow. The image likely demonstrates a step in the preparation or administration of the Susvimo intravitreal injection.*

FDA Label Image

Figure 8 (Susvimo 08)

An instructional illustration showing the proper handling of a syringe with a needle cap guard, demonstrating how to hold and prepare it for injection. The image depicts two hands holding the device, likely to guide the intravitreal injection process.*

FDA Label Image

Figure 9 (Susvimo 09)

An instructional illustration showing a hand holding the Susvimo injection device, with a finger pressing the plunger at the bottom and an upward arrow indicating the direction of injection or actuation, likely demonstrating proper administration technique for the intravitreal injection solution of ranibizumab.*

FDA Label Image

Figure 10 (Susvimo 10)

An instructional diagram depicting two stages of handling a SUSVIMO injection device. The left side shows an upward arrow indicating removal of a protective cap or cover from the top of the injection component, while the right side shows the device with the cover removed, revealing the injection tip. The illustration uses a blue background and grayscale device details.*

FDA Label Image

Image (Susvimo 100)

FDA Label Image

Image (Susvimo 101)

FDA Label Image

Image (Susvimo 102)

FDA Label Image

Image (Susvimo 103)

FDA Label Image

Image (Susvimo 104)

FDA Label Image

Image (Susvimo 105)

The image shows a sterile vial label for Susvimo injection, solution, containing Ranibizumab at 100 mg/mL. The label features the designation 'STERILE' and a clear indication of the right-side orientation with the letter 'R'. The vial label is from Genentech, Inc.*

FDA Label Image

Image (Susvimo 106)

Susvimo 100 mg/mL injection, solution in a vial, labeled for intravitreal use. The white vial has a blue cap and contains clear solution. The label shows the proprietary name Susvimo, the active ingredient Ranibizumab, and the manufacturer Genentech, Inc.*

FDA Label Image

Image (Susvimo 107)

An illustration showing a thermometer with a low temperature reading, indicated by a line extending from the bulb at the bottom to near the top of the scale. The thermometer is upright and simple in design.*

FDA Label Image

Image (Susvimo 108)

FDA Label Image

Image (Susvimo 109)

The image shows a black and white label with the word 'LOT' centered inside a rectangular border, indicating the space where the lot number for product identification would be printed. No other information or branding is visible in the image.*

FDA Label Image

Figure 11 (Susvimo 11)

An instructional diagram showing the tip of a syringe, highlighting the absence of an air bubble in the solution before injection. The image focuses on proper preparation technique for intravitreal injection of Susvimo (ranibizumab) injection, solution.*

FDA Label Image

Image (Susvimo 110)

FDA Label Image

Image (Susvimo 111)

Text panel labeled 'MR Conditional' indicating that a person implanted with a Susvimo Ocular Implant can be safely scanned with MRI under specific conditions. Includes a warning about potential injury or device malfunction if scanned under other conditions. The panel references MRI safety information found in the Instructions for Use and displays the Genentech, Inc. company logo and address.*

FDA Label Image

Image (Susvimo 112)

The image shows a Susvimo Implant Card with labeled blank lines for filling in patient information, including Patient Name, Physician Name, Clinic Name, Clinic Phone Number, Date of Implantation, and Implant LOT Number. The card is related to the Susvimo implant for ranibizumab.*

FDA Label Image

Figure 1 (Susvimo 113)

Carton image for Susvimo implant tool by Genentech, Inc. The label references an explant tool packaged in a sterile blister and includes an implant removal procedure instruction leaflet. The product supports the ranibizumab intravitreal injection system but does not show drug dosage detail on this carton.*

FDA Label Image

Figure 2 (Susvimo 114)

An instructional illustration of a blue tool with labeled finger grips and contoured tips, showing ergonomic features designed for handling or application support.*

FDA Label Image

Image (Susvimo 115)

FDA Label Image

Figure 3 (Susvimo 116)

Illustration showing a medical device or implant placed inside an eye. The image includes detailed depictions of ocular structures and the device being manipulated with surgical instruments, likely representing an intravitreal procedure related to Susvimo (ranibizumab injection).*

FDA Label Image

Figure 4 (Susvimo 117)

An anatomical instructional illustration showing an eye with the eyelid lifted by a surgical instrument. A red dashed line outlines an incision path along the lower eyelid, depicting a surgical approach likely related to the administration or implantation procedure associated with the drug Susvimo.*

FDA Label Image

Figure 5 (Susvimo 118)

An anatomical illustration showing a stylized human eye, including the iris, pupil, and sclera, with surrounding blood vessels visible. The image likely represents the ocular area relevant to intravitreal injections like Susvimo (Ranibizumab).*

FDA Label Image

Figure 6 (Susvimo 119)

Illustration showing a medical device or instrument being clipped or adjusted onto the eye, with an inset detail highlighting alignment through the eye's pupil. This instructional diagram depicts a step likely related to intravitreal injection or ocular surgery involving precise placement.*

FDA Label Image

Figure 12 (Susvimo 12)

An instructional diagram showing a step in the preparation or assembly of Susvimo (ranibizumab) injection, solution, 100 mg/mL. The illustration depicts hands positioning a syringe-like device to be inserted or connected to a blue component, indicating assembly or activation of the injection device by Genentech, Inc.*

FDA Label Image

Image (Susvimo 120)

FDA Label Image

Figure 7 (Susvimo 121)

An instructional illustration showing a surgical or medical procedure involving an eye. The diagram includes tools manipulating a device placed on the eye's surface, with a zoomed-in inset highlighting the positioning or alignment on the eye. This likely relates to the administration or implantation context for Susvimo injection, solution.*

FDA Label Image

Figure 8 (Susvimo 122)

Illustration showing a medical procedure involving the Susvimo intravitreal injection device. The image depicts a gloved hand holding a tool that is engaging with the implant insertion site on an eye model, with forceps assisting in the procedure. This diagram highlights the handling or insertion process for the Susvimo implant system.*

FDA Label Image

Figure 9 (Susvimo 123)

An instructional illustration showing an intravitreal injection procedure into the eye. The main image depicts a syringe positioned near the eye, with a red dashed line indicating the injection site. An inset shows a close-up view of the needle entering the eye near the cornea and lens.*

FDA Label Image

Figure 10 (Susvimo 124)

An instructional illustration depicting a surgical procedure involving an ocular implant device placed in the eye. Surgical tools and a cannula or tubing are shown interacting with the implant, indicating a step likely related to administering an intravitreal injection using the Susvimo implant system.*

FDA Label Image

Image (Susvimo 125)

FDA Label Image

Figure 11 (Susvimo 126)

An instructional anatomical illustration showing an ocular procedure involving an intravitreal injection. The image depicts a close-up of the eye with a medical instrument inserted, highlighting an area with a surgical patch and sutures, indicated by a red arrow, likely demonstrating a placement or treatment site on or near the sclera.*

FDA Label Image

Image (Susvimo 127)

FDA Label Image

Figure 12 (Susvimo 128)

An anatomical illustration showing the placement of the Susvimo implant in the eye. The image depicts the implant inserted into the scleral region, secured with sutures as indicated by a red arrow, illustrating the intravitreal route of administration for Ranibizumab injection solution.*

FDA Label Image

Image (Susvimo 129)

FDA Label Image

Figure 13 (Susvimo 13)

An instructional illustration showing the assembly or connection of a blue injection device, likely representing the Susvimo ranibizumab intravitreal injection system. The diagram features two hands positioning the parts to be joined, indicated by a leftward blue arrow.*

FDA Label Image

Image (Susvimo 130)

FDA Label Image

Image (Susvimo 131)

FDA Label Image

Image (Susvimo 132)

FDA Label Image

Image (Susvimo 133)

An instructional illustration showing an open booklet with an information symbol on one page, representing a patient information or instruction leaflet.*

FDA Label Image

Image (Susvimo 134)

The image shows a sterile label with a capital letter "R" enclosed in a square border, indicating the right side or right eye for administration. There is no further product information visible on this label.*

FDA Label Image

Image (Susvimo 135)

FDA Label Image

Image (Susvimo 136)

FDA Label Image

Image (Susvimo 137)

FDA Label Image

Principal Display Panel (Kit Carton)

Label for Susvimo (ranibizumab injection) 100 mg/mL, an intravitreal injection solution by Genentech, Inc. The label indicates the vial contains 10 mg/0.1 mL ranibizumab and is for use with the Susvimo ocular implant. It includes one single-dose vial and one initial fill needle, with instructions referenced for use with the insertion tool assembly.*

FDA Label Image

Principal Display Panel (10 mg/0.1 mL Vial Carton)

Label of Susvimo (ranibizumab injection) 100 mg/mL, a single-dose vial for intravitreal injection. The label specifies it is for use with the Susvimo ocular implant and instructs to dispense the enclosed Medication Guide to each patient. The product is manufactured by Genentech, Inc.*

FDA Label Image

Figure 14 (Susvimo 14)

An illustration showing a cross-sectional view of a medical device held by two hands, depicting internal components including a small, complex mechanism near one end inside a blue casing, likely representing a part of an injection system or delivery device for intravitreal administration.*

FDA Label Image

Figure 15 (Susvimo 15)

An instructional diagram showing a device component labeled within a dashed box marked "Sterile Field." The component appears to be an elongated, narrow tip, likely part of the Susvimo injection system for intravitreal delivery.*

FDA Label Image

Figure 16 (Susvimo 16)

An instructional diagram showing the assembly and preparation of an intravitreal injection device for Susvimo (ranibizumab) 100 mg/mL. The steps illustrate removing the cap, twisting to attach the needle, and pulling the needle cover off before injection.*

FDA Label Image

Susvimo 16a

An instructional illustration showing a pair of hands holding and preparing a syringe, likely demonstrating the proper technique to pull back the plunger or prepare the injection. The syringe appears to be a standard medical syringe with a needle attached at the tip.*

FDA Label Image

Figure 17 (Susvimo 17)

Illustration showing the steps to remove the cap from a syringe. The image depicts an initial downward arrow to indicate pressing the cap, followed by a twisting motion to unscrew the cap from the syringe, and then an upward arrow to indicate pulling the cap off, exposing the needle.*

FDA Label Image

Figure 18 (Susvimo 18)

An instructional diagram showing hands holding a syringe of Susvimo (Ranibizumab) injection, solution 100 mg/mL. The illustration highlights an air bubble in the syringe barrel and demonstrates a finger flicking the syringe to remove the air bubble before administration.*

FDA Label Image

Figure 19 (Susvimo 19)

An instructional illustration showing a hand holding a syringe with a close-up detail of the syringe barrel and dosage markings, highlighting the 0.1 mL measurement. The image focuses on accurate dosage measurement for intravitreal injections.*

FDA Label Image

Figure 20 (Susvimo 20)

An instructional diagram showing a hand holding a syringe of Susvimo (Ranibizumab) injection, solution 100 mg/mL. The illustration highlights the syringe barrel with labels pointing to indicate the absence of air bubbles in the syringe.*

FDA Label Image

Figure 21 (Susvimo 21)

An instructional illustration showing a close-up view of an eye being operated on with a medical instrument and a swab or applicator tip inside the eye. The surrounding structures and surgical tools are partially visible, indicating a procedural step involving the ocular surface or anterior chamber.*

FDA Label Image

Figure 22 (Susvimo 22)

An instructional illustration showing the intravitreal injection administration of Susvimo (Ranibizumab) 100 mg/mL. The diagram depicts a syringe injecting the solution through the sclera into the vitreous humor of the eye.*

FDA Label Image

Figure 23 (Susvimo 23)

An instructional illustration showing a close-up of an eye with a swab near the injection site and a syringe angled toward the eye. The depiction suggests preparation for an intravitreal injection, highlighting the application site and the use of a swab prior to medication administration.*

FDA Label Image

Figure 24 (Susvimo 24)

Illustration showing an intravitreal injection procedure labeled with parts including the soft stop, conjunctiva, and flange on the eye. The diagram depicts the interaction of the injection device with the ocular surface during administration.*

FDA Label Image

Figure 25 (Susvimo 25)

An instructional illustration showing an intravitreal injection procedure involving a fluid collection reservoir. The diagram highlights the fluid flow path with arrows, depicting insertion into the eye and fluid movement toward the reservoir.*

FDA Label Image

Figure 26 (Susvimo 26)

An instructional illustration showing the administration of an ocular injection, depicting a syringe needle approaching a specific entry point on the eye surface, indicated by a red arrow, with a cotton swab near the eye. This likely represents the intravitreal injection procedure related to Susvimo (ranibizumab) injection, solution.*

FDA Label Image

Figure 27 (Susvimo 27)

A line graph comparing adjusted mean BCVA change from baseline over 48 weeks for Susvimo Q24W 100 mg/mL injection versus intravitreal ranibizumab 0.5 mg Q4W injection. The x-axis represents time in weeks, and the y-axis shows change in BCVA letters. Two lines show visual acuity trends with corresponding sample sizes noted.*

FDA Label Image

Figure 28 (Susvimo 28)

Illustration showing the packaging components of Susvimo (ranibizumab injection) 100 mg/mL. The first carton contains a refill needle in a sterile blister pack. The second carton contains one vial of Susvimo injection and one prescribing information leaflet.*

FDA Label Image

Figure 29 (Susvimo 29)

An illustration diagram showing a side and cross-sectional view of a medical device component labeled with parts including the release control element, extrascleral flange, and septum.*

FDA Label Image

Figure 30 (Susvimo 30)

Susvimo vial containing 100 mg/mL Ranibizumab injection, solution for intravitreal use. The vial has a blue cap and clear glass body. Labeler is Genentech, Inc.*

FDA Label Image

Figure 31 (Susvimo 31)

An instructional diagram showing a two-part injection device for Susvimo (ranibizumab) 100 mg/mL solution. The components labeled include the Cap, Vented needle with Soft stop, Fluid collection reservoir, and Luer hub.*

FDA Label Image

Figure 1 (Susvimo 32)

Diagram illustrating the packaging components of Susvimo (ranibizumab injection) 100 mg/mL. It shows two main cartons: one contains the Susvimo insertion tool assembly with the insertion tool and implant in a sterile blister, plus an initial fill and implant procedure instruction for use; the other contains the initial fill needle kit with a needle in sterile blister, a vial of Susvimo injection, and United States prescribing information. Additional mention of a Susvimo explant tool available if needed.*

FDA Label Image

Figure 2 (Susvimo 33)

An instructional illustration showing a close-up view of a Susvimo injection device used for intravitreal administration of ranibizumab. The diagram highlights the applicator tip inside a protective enclosure, emphasizing the detailed structure of the injection component.*

FDA Label Image

Figure 3 (Susvimo 34)

Illustration diagram showing dimensions and labeled parts of a Susvimo implant device, including the release control element, body, silicone encasing, extrascleral flange, and septum, with measurements of 8.4 mm height, 2.6 mm width, and 4.6 mm flange diameter.*

FDA Label Image

Figure 4 (Susvimo 35)

An instructional diagram of the Susvimo implant showing components of the device. Labeled parts include the implant, gripper tips, luer lock slot, guide channel, and guide sleeve, illustrating the structure of the intravitreal injection system.*

FDA Label Image

Figure 5 (Susvimo 36)

An illustration of the Susvimo injection device showing a close-up of the release button located near one end of the device. The diagram highlights the release button component on the blue-colored intravitreal injection solution delivery system by Genentech, Inc.*

FDA Label Image

Figure 6 (Susvimo 37)

The image shows a vial with a blue cap and a blank white label on a transparent glass container. No specific product name, dosage, or manufacturer details are visible on the label.*

FDA Label Image

Figure 7 (Susvimo 38)

An instructional illustration showing two components of a medical injection device: a cap covering the needle and the needle assembly with a Luer hub. The image highlights the parts labeled "Cap," "Needle," and "Luer hub."*

FDA Label Image

Image (Susvimo 39)

Susvimo 100 mg/mL injection, solution in an intravitreal dosage form. The image shows a vial labeled with the proprietary name Susvimo and the active ingredient Ranibizumab, manufactured by Genentech, Inc. The vial cap is lavender-colored with the letters 'MR.'*

FDA Label Image

Image (Susvimo 40)

FDA Label Image

Figure 8 (Susvimo 41)

An instructional illustration showing the sterile field setup for Susvimo 100 mg/mL intravitreal injection. It depicts a blister tray containing a vial and an applicator tool, alongside a separate blue-colored component, all arranged within a defined sterile field area.*

FDA Label Image

Image (Susvimo 42)

FDA Label Image

Figure 9 (Susvimo 43)

An instructional illustration showing the position of an insertion tool in the eye for a Susvimo (ranibizumab) intravitreal injection. The diagram labels the nasal, temporal, superior, and inferior regions of the eye, with an inset indicating the implant site on the inferior retina.*

FDA Label Image

Figure 10 (Susvimo 44)

An anatomical illustration showing the eye with labeled quadrants: inferior, superior, nasal, and temporal. The image depicts the insertion of a needle or injection instrument in the temporal region of the eye, consistent with an intravitreal injection procedure.*

FDA Label Image

Figure 11 (Susvimo 45)

An instructional diagram illustrating the use of a 4mm marked tool or device interacting with a structure labeled 'eye' that appears to be part of an ocular implant or device. The image likely represents a step in the administration or adjustment process related to the Susvimo (ranibizumab injection, solution) intravitreal implant.*

FDA Label Image

Image (Susvimo 46)

FDA Label Image

Figure 12 (Susvimo 47)

An anatomical illustration showing the eye with an intravitreal injection procedure. A syringe or insertion tool is depicted approaching the eye, highlighting the injection site with an inset zoomed section. This diagram is intended to visually explain the administration of Susvimo (ranibizumab) injection into the eye.*

FDA Label Image

Image (Susvimo 48)

FDA Label Image

Susvimo 48a

An instructional line drawing showing two hands holding a syringe with a needle. The illustration appears to depict the preparation or use of an intravitreal injection device, consistent with the administration method for Susvimo (ranibizumab) injection solution.*

FDA Label Image

Figure 13 (Susvimo 49)

An instructional illustration showing the steps to attach and remove a needle from a syringe. The sequence includes aligning and twisting the needle onto the syringe hub, then attaching the full needle and syringe assembly. The directions are indicated with arrows for proper manipulation.*

FDA Label Image

Image (Susvimo 50)

FDA Label Image

Figure 14 (Susvimo 51)

An instructional diagram showing the steps to remove a blue protective cap from an injection device. The first step indicates pulling the cap straight down, the second step shows twisting the cap to unscrew it, and the third step depicts lifting the cap off vertically, revealing the tip of the injection device underneath.*

FDA Label Image

Figure 15 (Susvimo 52)

An instructional drawing showing a hands holding a syringe. The illustration focuses on the syringe barrel with a close-up circle highlighting an air bubble present inside. One hand is positioned to tap or flick the syringe barrel to move or remove the air bubble. This diagram likely relates to preparation or administration technique for an injection.*

FDA Label Image

Figure 16 (Susvimo 53)

Instructional illustration showing a pair of gloved hands preparing an intravitreal injection using a syringe. The image focuses on holding and handling the syringe for administration.*

FDA Label Image

Image (Susvimo 54)

FDA Label Image

Figure 17 (Susvimo 55)

An instructional illustration showing a hand holding a syringe filled with fluid. A magnified circular inset focuses on the syringe barrel near the needle, highlighting the absence of air bubbles inside the syringe and near the plunger. This diagram visually emphasizes ensuring no air bubbles are present in the injection solution before administration.*

FDA Label Image

Image (Susvimo 56)

FDA Label Image

Figure 18 (Susvimo 57)

Instructional illustration showing a step in the preparation or handling of an injection device. A hand holds a syringe above a blue device or housing, with an arrow indicating the syringe is to be inserted or aligned with the device. No text or labeling is visible in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.